1st Quarter - Report

PERSONALIZED MEDICINE COALITION for PERSONALIZED MEDICINE COALITION

Firm
Client
Income
—
Expenses
$40,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

FY 2025 Food and Drug Administration Budget Priorities for CDER, CBER and CDRH FY 2025 National Institutes of Health Budget Priorities

LobbyistCovered position, as disclosed
CYNTHIA BENS Staff, Representative Paul E. Kanjorski

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Health Issues HCR

Congressional Personalized Medicine Caucus Right Drug Dose Now Act Oversight of Laboratory Developed Tests AHRQ Draft Report Blood-based Tests for Multiple Cancer Screening: A Systematic Review CMS Implementation of Medicare Drug Price Negotiation Program/ Medicare Drug Price Negotiation Program Medicare and Medicaid Programs; Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (CMS-4208-P) Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community

LobbyistCovered position, as disclosed
CYNTHIA BENS Staff, Representative Paul E. Kanjorski
DAVID L DAVENPORT —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Centers For Medicare and Medicaid Services (CMS); Agency for Healthcare Research & Quality (AHRQ); Food & Drug Administration (FDA)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.